Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $1.28 trillion. The enterprise value is $1.32 trillion.
| Market Cap | 1.28T |
| Enterprise Value | 1.32T |
Important Dates
The last earnings date was Thursday, October 29, 2026, before market open.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Nov 13, 2026 |
Share Statistics
Eli Lilly has 890.75 million shares outstanding. The number of shares has decreased by -0.58% in one year.
| Current Share Class | 890.75M |
| Shares Outstanding | 890.75M |
| Shares Change (YoY) | -0.58% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 89.72% |
| Float | 888.43M |
Valuation Ratios
The trailing PE ratio is 46.65 and the forward PE ratio is 30.64. Eli Lilly's PEG ratio is 1.47.
| PE Ratio | 46.65 |
| Forward PE | 30.64 |
| PS Ratio | 14.81 |
| Forward PS | 12.74 |
| PB Ratio | 31.81 |
| P/TBV Ratio | 103.98 |
| P/FCF Ratio | 65.12 |
| P/OCF Ratio | 41.78 |
| PEG Ratio | 1.47 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.48, with an EV/FCF ratio of 67.35.
| EV / Earnings | 48.01 |
| EV / Sales | 15.31 |
| EV / EBITDA | 28.48 |
| EV / EBIT | 29.88 |
| EV / FCF | 67.35 |
Financial Position
The company has a current ratio of 1.39, with a Debt / Equity ratio of 1.23.
| Current Ratio | 1.39 |
| Quick Ratio | 0.64 |
| Debt / Equity | 1.23 |
| Debt / EBITDA | 1.06 |
| Debt / FCF | 2.52 |
| Interest Coverage | 115.70 |
Financial Efficiency
Return on equity (ROE) is 86.02% and return on invested capital (ROIC) is 42.68%.
| Return on Equity (ROE) | 86.02% |
| Return on Assets (ROA) | 21.06% |
| Return on Invested Capital (ROIC) | 42.68% |
| Return on Capital Employed (ROCE) | 43.84% |
| Weighted Average Cost of Capital (WACC) | 6.18% |
| Revenue Per Employee | $1.73M |
| Profits Per Employee | $551,600 |
| Employee Count | 50,000 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 0.93 |
Taxes
In the past 12 months, Eli Lilly has paid $7.19 billion in taxes.
| Income Tax | 7.19B |
| Effective Tax Rate | 20.68% |
Stock Price Statistics
The stock price has increased by +48.69% in the last 52 weeks. The beta is 0.39, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +48.69% |
| 50-Day Moving Average | 1,230.06 |
| 200-Day Moving Average | 1,105.21 |
| Relative Strength Index (RSI) | 70.30 |
| Average Volume (20 Days) | 3,067,247 |
Short Selling Information
The latest short interest is 6.96 million, so 0.78% of the outstanding shares have been sold short.
| Short Interest | 6.96M |
| Short Previous Month | 7.52M |
| Short % of Shares Out | 0.78% |
| Short % of Float | 0.78% |
| Short Ratio (days to cover) | 3.00 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $86.46 billion and earned $27.58 billion in profits. Earnings per share was $30.81.
| Revenue | 86.46B |
| Gross Profit | 72.31B |
| Operating Income | 44.32B |
| Pretax Income | 34.77B |
| Net Income | 27.58B |
| EBITDA | 46.49B |
| EBIT | 44.32B |
| Earnings Per Share (EPS) | $30.81 |
Balance Sheet
The company has $5.65 billion in cash and investments and $49.50 billion in debt, with a net cash position of -$43.86 billion or -$49.24 per share.
| Cash & Investments | 5.65B |
| Total Debt | 49.50B |
| Net Cash | -43.86B |
| Net Cash Per Share | -$49.24 |
| Equity (Book Value) | 40.27B |
| Book Value Per Share | 45.19 |
| Working Capital | 18.27B |
Cash Flow
In the last 12 months, operating cash flow was $30.65 billion and capital expenditures -$10.98 billion, giving a free cash flow of $19.66 billion.
| Operating Cash Flow | 30.65B |
| Capital Expenditures | -10.98B |
| Depreciation & Amortization | 2.17B |
| Net Borrowing | 7.32B |
| Free Cash Flow | 19.66B |
| FCF Per Share | $22.07 |
Margins
Gross margin is 83.63%, with operating and profit margins of 51.25% and 31.90%.
| Gross Margin | 83.63% |
| Operating Margin | 51.25% |
| Pretax Margin | 40.21% |
| Profit Margin | 31.90% |
| EBITDA Margin | 53.77% |
| EBIT Margin | 51.25% |
| FCF Margin | 22.74% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 0.48%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 0.48% |
| Dividend Growth (YoY) | 15.33% |
| Years of Dividend Growth | 11 |
| Payout Ratio | 22.46% |
| FCF Payout Ratio | 31.35% |
| Buyback Yield | 0.58% |
| Shareholder Yield | 1.06% |
| Earnings Yield | 2.14% |
| FCF Yield | 1.54% |
Analyst Forecast
The average price target for Eli Lilly is $1,460.30, which is 1.60% higher than the current price. The consensus rating is "Buy".
| Price Target | $1,460.30 |
| Price Target Difference | 1.60% |
| Analyst Consensus | Buy |
| Analyst Count | 31 |
| Revenue Growth Forecast (3Y) | 22.18% |
| EPS Growth Forecast (3Y) | 33.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 7.27 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.27 |
| Piotroski F-Score | 6 |